To date, evaluation of actionable alterations within EGFR and ALK genes and assessment of PD-L1 expression levels is part of the routine evaluation of ES-NSCLC [8,22], in order to select patients eligible for treatment with EGFR TKI [13] or immune checkpoint inhibitors [16,17]. Here, ALK is linked to non-small cell lung carcinoma.